Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS’ McClellan To Discuss Medicare Rx With AARP Board Feb. 1

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency chief will address the organization’s annual policy meeting less than two weeks after release of the final rules implementing Part D drug benefit. HHS Information Technology Coordinator Brailer is expected to discuss the e-prescribing draft rule.

You may also be interested in...



E-Prescribing Draft Rule Proposes Adoption Of Formulary Info Standards

The proposal would establish standards for delivering formulary information based on an RxHub protocol. Under the rule, formulary transmissions would include information on coverage, preferred alternative drugs and comparative copayments.

Medicare Rx Final Regs Retain CMS Right To Plans’ Drug Price Information

Agency releases final rules implementing Title I and II of the Medicare Modernization Act. CMS’ authority to evaluate data on drug prices negotiated by Medicare prescription drug plans does not violate the “non-interference” provision of MMA, reg states. Drug price reviews will be “rare,” CMS says.

House Appropriations Subcommittee Plans FDA Hearing July 26

Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel